Fremanezumab
- Generic Name
- Fremanezumab
- Brand Names
- Ajovy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1655501-53-3
- Unique Ingredient Identifier
- PF8K38CG54
- Background
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist ubro...
- Indication
Fremanezumab is indicated for the preventative treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1890
- Registration Number
- NCT02638103
- Locations
- ๐ต๐ฑ
Teva Investigational Site 53366, Lublin, Poland
๐ต๐ฑTeva Investigational Site 53365, Poznan, Poland
๐ฏ๐ตTeva Investigational Site 84061, Sendai-shi, Japan
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 875
- Registration Number
- NCT02629861
- Locations
- ๐บ๐ธ
Teva Investigational Site 13536, Springfield, Missouri, United States
๐บ๐ธTeva Investigational Site 13609, Akron, Ohio, United States
๐บ๐ธTeva Investigational Site 13634, Akron, Ohio, United States
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1130
- Registration Number
- NCT02621931
- Locations
- ๐บ๐ธ
Teva Investigational Site 13585, Chicago, Illinois, United States
๐บ๐ธTeva Investigational Site 13626, Columbus, Ohio, United States
๐บ๐ธTeva Investigational Site 13568, Encino, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.